Major Estimate Revision • May 14
Consensus estimates of losses per share improve by 36% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from US$647.8m to US$661.8m. EPS estimate increased from -US$0.227 per share to -US$0.145 per share. Healthcare industry in the US expected to see average net income growth of 26% next year. Consensus price target of US$7.00 unchanged from last update. Share price was steady at US$4.08 over the past week. Reported Earnings • May 11
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: US$0.021 loss per share (improved from US$0.21 loss in 1Q 2025). Revenue: US$147.4m (up 41% from 1Q 2025). Net loss: US$2.09m (loss narrowed 87% from 1Q 2025). Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) also surpassed analyst estimates by 77%. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 4.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 107% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 27
The Oncology Institute, Inc. to Report Q1, 2026 Results on May 07, 2026 The Oncology Institute, Inc. announced that they will report Q1, 2026 results on May 07, 2026 Recent Insider Transactions Derivative • Apr 16
Independent Director notifies of intention to sell stock Mohit Kaushal intends to sell 96k shares in the next 90 days after lodging an Intent To Sell Form on the 14th of April. If the sale is conducted around the recent share price of US$3.30, it would amount to US$316k. Since December 2025, Mohit has owned 217.38k shares directly. Company insiders have collectively sold US$2.3m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Apr 07
The Oncology Institute, Inc. Announces Appointment of Minh Merchant as Chief Legal Officer The Oncology Institute, Inc. announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Ms. Merchant will oversee legal, regulatory, compliance and privacy functions as TOI continues to scale. This role will be essential in enabling the company to continue its growth trajectory while further enhancing its mission to be a trusted healthcare partner to oncology patients and payors. Ms. Merchant has more than two decades of experience advising public and private healthcare organizations, including significant experience in transactional, regulatory and compliance matters. She previously served as general counsel at Midi Health, Kyverna Therapeutics, Aspira Women’s Health and McKesson, and holds a JD from UCLA School of Law. Major Estimate Revision • Mar 19
Consensus estimates of losses per share improve by 24% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from US$636.2m to US$647.8m. EPS estimate increased from -US$0.297 per share to -US$0.227 per share. Healthcare industry in the US expected to see average net income growth of 25% next year. Consensus price target up from US$6.50 to US$7.00. Share price rose 35% to US$3.54 over the past week. Reported Earnings • Mar 13
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: US$0.66 loss per share. Revenue: US$502.7m (up 28% from FY 2024). Net loss: US$60.6m (loss widened 14% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 8.1%. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 4.9% growth forecast for the Healthcare industry in the US. Announcement • Mar 13
The Oncology Institute, Inc., Annual General Meeting, Jun 17, 2026 The Oncology Institute, Inc., Annual General Meeting, Jun 17, 2026. Announcement • Feb 26
The Oncology Institute, Inc. to Report Q4, 2025 Results on Mar 12, 2026 The Oncology Institute, Inc. announced that they will report Q4, 2025 results on Mar 12, 2026 Announcement • Feb 23
The Oncology Institute, Inc. Appoints Kim Tzoumakas to Board of Directors The Oncology Institute, Inc. announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has served on the board of several private and public healthcare companies including SeaSpine, Coherus BioSciences, Ob Hospitalist Group and most recently, VytlOne. Announcement • Jan 13
The Oncology Institute, Inc. Provides Earnings Guidance for 2026 The Oncology Institute, Inc. provided earnings guidance for 2026. The company anticipated that total revenue will be in the range of $630 million to $650 million, reflecting 28% growth from the midpoint of 2025 and 2026 guidance. Announcement • Jan 09
the Oncology Institute, Inc. Announces Executive Changes The Oncology Institute, Inc. announced the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer, Rakesh Panda has more than 25 years of experience across IT, digital transformation, cybersecurity, and enterprise software development, including leadership roles at Cisco and Infosys. Mr. Panda will continue to guide TOI’s technology strategy, including AI-enablement efforts and enterprise-level data privacy and security practices. Nolan Mariano has 18 years of experience in People Operations and organizational leadership across several industries. Mr. Mariano joined TOI in 2022 and, as Chief People Officer, will oversee HR Operations, Total Rewards, Learning and Development, and Talent Acquisition functions. Announcement • Jan 06
The Oncology Institute Announces Addition of Mark Stolper to the Board of Directors, Effective January 2, 2026 The Oncology Institute, Inc. announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute’s board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc., a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21stCentury Oncology Holdings, Inc., which at the time was one of the nation’s leading radiation and medical oncology companies. Recent Insider Transactions • Dec 19
Vice Chairman recently sold US$50k worth of stock On the 15th of December, Bradford Hively sold around 13k shares on-market at roughly US$3.77 per share. This transaction amounted to 2.3% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$200k. Bradford has been a net seller over the last 12 months, reducing personal holdings by US$444k. Announcement • Dec 02
The Oncology Institute, Inc. Announces Resignation of Board Member Gabe Ling, Effective December 1, 2025 The Oncology Institute, Inc. announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise. Major Estimate Revision • Nov 25
Consensus EPS estimates fall by 10%, revenue upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$475.1m to US$500.6m. Forecast EPS reduced from -US$0.533 to -US$0.587 per share. Healthcare industry in the US expected to see average net income growth of 27% next year. Consensus price target of US$6.50 unchanged from last update. Share price fell 16% to US$3.16 over the past week. Recent Insider Transactions • Nov 23
Independent Director recently sold US$200k worth of stock On the 18th of November, Mark Pacala sold around 50k shares on-market at roughly US$4.00 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$544k more than they bought in the last 12 months. Recent Insider Transactions Derivative • Nov 20
Independent Director notifies of intention to sell stock Mark Pacala intends to sell 50k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of November. If the sale is conducted around the recent share price of US$4.00, it would amount to US$200k. Since December 2024, Mark's direct individual holding has increased from 84.41k shares to 174.97k. Company insiders have collectively sold US$4.0m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Nov 14
Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2025 results: US$0.17 loss per share. Revenue: US$136.6m (up 37% from 3Q 2024). Net loss: US$16.5m (loss widened 25% from 3Q 2024). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 24%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Healthcare industry in the US. Announcement • Nov 14
The Oncology Institute, Inc. Updates Earnings Guidance for the Full Year of 2025 The Oncology Institute, Inc. updated earnings guidance for the full year of 2025. For the period, Company is raising revenue outlook from $460 million to $480 million to a range of $495 million to $505 million. Announcement • Oct 23
The Oncology Institute, Inc. to Report Q3, 2025 Results on Nov 13, 2025 The Oncology Institute, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025 Board Change • Oct 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. CEO & Executive Director Dan Virnich was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Aug 24
Vice Chairman recently sold US$82k worth of stock On the 19th of August, Bradford Hively sold around 20k shares on-market at roughly US$4.06 per share. This transaction amounted to 4.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$312k. Bradford has been a net seller over the last 12 months, reducing personal holdings by US$344k. Major Estimate Revision • Aug 20
Consensus EPS estimates fall by 15%, revenue upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$466.8m to US$475.1m. Forecast EPS reduced from -US$0.477 to -US$0.547 per share. Healthcare industry in the US expected to see average net income growth of 24% next year. Consensus price target of US$7.00 unchanged from last update. Share price fell 8.8% to US$3.74 over the past week. Reported Earnings • Aug 14
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2025 results: US$0.18 loss per share (further deteriorated from US$0.17 loss in 2Q 2024). Revenue: US$119.8m (up 22% from 2Q 2024). Net loss: US$17.0m (loss widened 34% from 2Q 2024). Revenue exceeded analyst estimates by 5.9%. Earnings per share (EPS) missed analyst estimates by 25%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Announcement • Jul 25
The Oncology Institute, Inc. to Report Q2, 2025 Results on Aug 13, 2025 The Oncology Institute, Inc. announced that they will report Q2, 2025 results After-Market on Aug 13, 2025 Announcement • Jul 15
The Oncology Institute, Inc. Names Kristin England as Chief Administrative Officer, Effective July 7, 2025 The Oncology Institute, Inc. announced that Kristin England has joined the organization as Chief Administrative Officer (CAO), effective July 7, 2025. In this newly established role, England will oversee Enterprise Central Business Operations and Technology Strategy and Enablement across TOI’s expanding national footprint. England brings over two decades of leadership experience in healthcare management and operations, most recently serving as a senior executive within McKesson’s US Oncology Network. There, she led high-performing teams focused on optimizing revenue cycle performance and streamlining practice management systems to drive operational efficiency and service delivery. New Risk • Jun 26
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$312k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$3.2m net loss in 2 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Significant insider selling over the past 3 months (US$312k sold). Recent Insider Transactions Derivative • Jun 08
Vice Chairman exercised options and sold US$3.7m worth of stock On the 3rd of June, Bradford Hively exercised 2m options at a strike price of around US$0.48 and sold these shares for an average price of US$2.45 per share. This trade did not impact their existing holding. Since June 2024, Bradford's direct individual holding has increased from 417.98k shares to 504.93k. Company insiders have collectively sold US$3.9m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Jun 07
The Oncology Institute, Inc. has filed a Follow-on Equity Offering in the amount of $15 million. The Oncology Institute, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering New Risk • May 20
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$6.3m net loss in 2 years). Shareholders have been diluted in the past year (18% increase in shares outstanding). Reported Earnings • May 15
First quarter 2025 earnings released: US$0.25 loss per share (vs US$0.22 loss in 1Q 2024) First quarter 2025 results: US$0.25 loss per share (further deteriorated from US$0.22 loss in 1Q 2024). Revenue: US$104.4m (up 10% from 1Q 2024). Net loss: US$19.6m (loss widened 20% from 1Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. Announcement • May 15
The Oncology Institute, Inc. Reaffirms Earnings Guidance for the Year 2025 The Oncology Institute, Inc. reaffirmed earnings guidance for the year 2025. For the period, Company expects Revenue of $460 million to $480 million. Announcement • May 08
The Oncology Institute to Present at Upcoming ASCO Annual Meeting on High-Value Cancer Care Model Outcomes Showing Cost Savings and Lower Hospitalization Rates The Oncology Institute, Inc. announced that it has been selected to present an abstract at the upcoming ASCO Annual Meeting further validating cost savings and reduced hospitalizations associated with its unique High-Value Cancer Care (HVCC) model. The study shares new data supporting prior publications which demonstrate superior outcomes for acute-care patients when enrolled in the TOI HVCC model. Summary of Outcomes of the Most Recent Clinical Trial Analysis: 53% Lower Emergency Department Use; 68% Lower Hospitalizations; 75% Lower Odds of Acute Care Facility Death; Lower Total Cost of Care by $12,000 per Enrolled Patient;atel, et al. Improving care of older adults with cancer: A randomized trial. ASCO Annual Meeting Health Services Section, May 30, 2025. Announcement • Apr 23
The Oncology Institute, Inc. to Report Q1, 2025 Results on May 14, 2025 The Oncology Institute, Inc. announced that they will report Q1, 2025 results After-Market on May 14, 2025 Announcement • Mar 31
The Oncology Institute, Inc. Launches Florida Oncology Network, a Fully Delegated Cancer Care Network, and Announces Four Additional Value-Based Contracts in First Quarter The Oncology Institute, Inc. announced the launch of the Florida Oncology Network. This new fully delegated network will expand access to high-quality, coordinated cancer care for Florida residents. The Florida Oncology Network includes TOI Clinics and a robust panel of value-focused medical and radiation oncologists strategically located throughout the state. The network is designed to provide comprehensive cancer care that is accessible, affordable, and focused on outcomes for patients and payor partners. Under the delegated arrangement, TOI has partnered with Provider Network Solutions (PNS), the market leader in specialty MSO and third-party administrative services, and through its affiliates will provide claims administration and processing as well as network management. The collaboration brings together TOI's nationally recognized clinical model and PNS's deep experience supporting delegated provider networks in Florida. Together, the organizations will focus on improving patient outcomes, reducing unnecessary variation in care, and aligning incentives with value-based objectives. The Florida Oncology network commences operations effective immediately, with plans to grow both its geographic footprint and patient reach across Florida throughout 2025. This comes alongside 80,000 additional lives already signed in 2025 to date, through four separate agreements across markets, including over 42,000 Medicare Advantage lives in the new fully delegated model in Florida. Announcement • Mar 27
The Oncology Institute, Inc. announced that it has received $16.499994 million in funding On March 26, 2025, The Oncology Institute, Inc., closed the transaction. Announcement • Mar 26
The Oncology Institute, Inc. Provides Earnings Guidance for the Year 2025 The Oncology Institute, Inc. provided earnings guidance for the year 2025. The company expects revenue of $460 to $480 million. Announcement • Mar 25
The Oncology Institute, Inc. announced that it expects to receive $16.499999 million in funding The Oncology Institute, Inc. entered into a securities purchase agreement to issue issue an aggregate of 12,006,510 shares of the Company’s common stock at a price of $1.37425446 per share, par value $0.0001 per share, pre-funded warrants to purchase up to an aggregate of 2,886,614 shares of Common Stock and accompanying common warrants to purchase up to an aggregate of 7,446,562 shares of Common Stock for the gross proceeds of $16,500,000 on March 24, 2025. The pre-funded warrants will have an exercise price of $0.0001 per share until exercised in full, and the common warrants will have an exercise price of $1.1980 per share. The transaction includes participation from existing investors, as well as members of the company’s management team and board of directors and is expected to close on March 26, 2025, subject to customary closing conditions. The offer and sale of the foregoing securities will be made by TOI in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and/or Regulation D promulgated thereunder, or in the case of the exchange transaction with Deerfield Section 3(a)(9) of the Act, and such securities have not been registered under the Act or applicable state securities laws. The company will issue Reported Earnings • Mar 24
Full year 2024 earnings released: US$0.86 loss per share (vs US$0.92 loss in FY 2023) Full year 2024 results: US$0.86 loss per share (improved from US$0.92 loss in FY 2023). Revenue: US$393.4m (up 21% from FY 2023). Net loss: US$64.7m (loss narrowed 4.7% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance. Announcement • Mar 17
The Oncology Institute, Inc., Annual General Meeting, May 07, 2025 The Oncology Institute, Inc., Annual General Meeting, May 07, 2025. Announcement • Mar 04
The Oncology Institute, Inc. to Report Q4, 2024 Results on Mar 25, 2025 The Oncology Institute, Inc. announced that they will report Q4, 2024 results After-Market on Mar 25, 2025 Announcement • Dec 20
The Oncology Institute Gets 180 Days Extension to Regain Compliance with Nasdaq Minimum Bid Price On June 20, 2024, The Oncology Institute, Inc. (the Company") received a letter (the First Nasdaq Bid Price Letter") from The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company is no longer in compliance with Nasdaq Listing Rule 5550(a)(2), because the minimum bid price of the Company's common stock (the Common Stock") had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until December 17, 2024, to regain compliance. As of the date of this report the Common Stock has not regained compliance with the Minimum Bid Price Requirement. However, in a letter dated December 19, 2024 (the Second Nasdaq Bid Price Letter"), Nasdaq notified the Company that Nasdaq's Staff has determined that the Company is eligible for an additional 180 calendar day period, or until June 16, 2025, to regain compliance (the Second Compliance Period"). The determination is based on the Company's meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market with the exception of the Minimum Bid Price Requirement, and the Company's written notice of its intention to cure the deficiency during the Second Compliance Period by effecting a reverse stock split, if necessary. If the Company chooses to implement a reverse stock split, it must complete the split no later than ten business days prior to the end of the Second Compliance Period in order to timely regain compliance. The Second Nasdaq Bid Price Letter has no immediate effect on the listing or trading of the Common Stock. The Company intends to cure the deficiency between now and the expiration of the Second Compliance Period and will consider all available options to resolve the deficiency including effecting a reverse stock split, if necessary, with every intention to regain compliance with the Minimum Bid Price Requirement. However, if the Company does not regain compliance by the end of the Second Compliance Period, Nasdaq will notify the Company that its securities would be subject to delisting. In the event of such a notification, the Company may appeal the Nasdaq Staff's determination to delist its securities before the Nasdaq Hearings Panel (the Panel"). However, there can be no assurance that, in the event of such appeal, the Panel would grant the Company's request for continued listing. New Risk • Dec 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 62% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Market cap is less than US$100m (US$11.7m market cap). New Risk • Nov 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.98m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 62% per year over the past 5 years. Market cap is less than US$10m (US$9.98m market cap). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Reported Earnings • Nov 15
Third quarter 2024 earnings released: US$0.21 loss per share (vs US$0.19 loss in 3Q 2023) Third quarter 2024 results: US$0.21 loss per share (further deteriorated from US$0.19 loss in 3Q 2023). Revenue: US$99.9m (up 22% from 3Q 2023). Net loss: US$16.1m (loss widened 13% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 10 percentage points per year, which is a significant difference in performance. Announcement • Nov 12
The Oncology Institute, Inc. Receives Certification to Begin Administering Pluvicto Therapy in their Outpatient California Radiation Oncology Practices The Oncology Institute, Inc. and its affiliates announced that they have received certification to begin administering Pluvicto therapy in their outpatient California radiation oncology practices. Pluvicto, a radiopharmaceutical used to treat certain types of metastatic prostate cancer, has previously been administered primarily in hospital settings. Announcement • Nov 05
The Oncology Institute, Inc. to Report Q3, 2024 Results on Nov 13, 2024 The Oncology Institute, Inc. announced that they will report Q3, 2024 results After-Market on Nov 13, 2024 Announcement • Sep 25
The Oncology Institute Announces CFO Changes The Oncology Institute (TOI) has revealed a significant change in its executive team, announcing the upcoming departure of chief financial officer Mihir Shah. Effective 14 October, Shah will leave TOI to explore new opportunities. Stepping into the role will be Rob Carter, who is currently serving as TOI's finance senior vice president. Carter has more than ten years of leadership experience in finance within the healthcare sector. Since joining the institute in 2021, Carter has been instrumental in managing corporate finance, financial planning, and analysis (FP&A), and investor relations. Rob brings a wealth of experience in both oncology and large health systems, has been instrumental to the finance operations over the last several years, and is the right leader for the next phase of TOI's growth. New Risk • Sep 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (US$24.9m market cap). Reported Earnings • Aug 15
Second quarter 2024 earnings released: US$0.17 loss per share (vs US$0.19 loss in 2Q 2023) Second quarter 2024 results: US$0.17 loss per share (improved from US$0.19 loss in 2Q 2023). Revenue: US$98.6m (up 23% from 2Q 2023). Net loss: US$12.7m (loss narrowed 8.3% from 2Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 6.8% growth forecast for the Healthcare industry in the US. Announcement • Aug 14
The Oncology Institute, Inc. Updates Earnings Guidance for the Full Year 2024 The Oncology Institute, Inc. updates earnings guidance for the full year 2024. For the period, the company expects revenue to be $400 million to $415 million as compared to the previous guidance of $400 million to $415 million. New Risk • Aug 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$49m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (US$36.8m market cap). Announcement • Jul 23
The Oncology Institute, Inc. to Report Q2, 2024 Results on Aug 13, 2024 The Oncology Institute, Inc. announced that they will report Q2, 2024 results After-Market on Aug 13, 2024 Announcement • Jun 22
The Oncology Institute, Inc. Receives A Written Notice from the Nasdaq Stock Market LLC On June 20, 2024, The Oncology Institute, Inc. (the Company") received a written notice from The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company is no longer in compliance with Nasdaq Listing Rule 5550(a)(2), because the minimum bid price of the Company's Common Stock has been below $1.00 per share for 30 consecutive business days (the Notice"). The Notice has no immediate effect on the listing or trading of the Company's Common Stock or Warrants on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until December 17, 2024 (the Compliance Date"), to regain compliance with the minimum bid price requirement. If at any time before the Compliance Date the bid price for the Common Stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide written notification to the Company that it has regained compliance with the minimum bid price requirement. In the event the Company does not regain compliance with the minimum bid price requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would be required, among other things, to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and would also need to provide written notice to Nasdaq of its intention to cure the bid price deficiency during the additional compliance period. If the Company fails to regain compliance during the compliance period (including a second compliance period, if applicable), then Nasdaq will notify the Company of its determination to delist its Common Stock and Warrants, at which point the Company may appeal Nasdaq's delisting determination to a Nasdaq hearing panel. The Company intends to actively monitor the closing bid price of its Common Stock and will consider all available options to regain compliance with the minimum bid price requirement, which may include seeking stockholder approval to effect a reverse stock split. In the event the Company chooses to implement a reverse stock split to regain compliance, such action must be completed at least ten business days prior to the original Compliance Date or the 180-day extension, whichever is applicable. There can be no assurance that the Company will regain compliance with the minimum bid price requirement during the 180 calendar day compliance period, secure an additional 180 calendar day period to regain compliance, maintain compliance with the other Nasdaq listing requirements or be successful in appealing any delisting determination. Reported Earnings • May 16
First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.33 loss in 1Q 2023) First quarter 2024 results: US$0.27 loss per share (improved from US$0.33 loss in 1Q 2023). Revenue: US$94.7m (up 24% from 1Q 2023). Net loss: US$19.9m (loss narrowed 19% from 1Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Healthcare industry in the US. Announcement • May 16
The Oncology Institute, Inc. Reaffirms Earnings Guidance for the Year 2024 The Oncology Institute, Inc. reaffirmed earnings guidance for the year 2024. For the year 2024, the company expects revenue of $400 million to $415 million. Announcement • May 03
The Oncology Institute, Inc., Annual General Meeting, Jun 13, 2024 The Oncology Institute, Inc., Annual General Meeting, Jun 13, 2024, at 11:00 Pacific Standard Time. Agenda: To consider Election of directors; to consider ratification of the appointment of BDO USA, P.C. as the independent registered public accounting firm of the Company for 2024; to approve for the purposes of Nasdaq Listing Rule 5635, of the issuances of the maximum number of shares of Common Stock underlying Secured Senior Convertible Notes and Warrants to purchase Common Stock; and to consider any other matters. Announcement • Apr 24
The Oncology Institute, Inc. to Report Q1, 2024 Results on May 14, 2024 The Oncology Institute, Inc. announced that they will report Q1, 2024 results After-Market on May 14, 2024 New Risk • Apr 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$95.1m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$36m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$95.1m market cap). Announcement • Apr 09
The Oncology Institute, Inc. Appoints Jordan McInerney as New Chief Development Officer The Oncology Institute, Inc. announced the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving M&A processes for acquisition targets, and establishing MSO platforms to deliver value-based oncology care nationwide. Bringing over 15 years of healthcare leadership, McInerney most recently served as the Chief Operations Officer of HOPCo Network Solutions. Here, he oversaw the operations and expansion of musculoskeletal capitation networks. His tenure at HOPCo encompassed various executive positions, including Executive Vice President of Growth & Network Strategies and Executive Vice President of Value Based Care. Notably, Mclnerney played a pivotal role in business development, strategic partnerships, and facilitating acquisitions. Prior to his time at HOPCo, he held various sales and operations leadership roles at Stryker, where he focused on value-based care solutions, customer alignment strategies and business development. Reported Earnings • Mar 29
Full year 2023 earnings released: US$0.92 loss per share (vs US$0.001 profit in FY 2022) Full year 2023 results: US$0.92 loss per share (down from US$0.001 profit in FY 2022). Revenue: US$324.2m (up 28% from FY 2022). Net loss: US$67.9m (down US$67.9m from profit in FY 2022). Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 6.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance. Announcement • Mar 28
The Oncology Institute, Inc. Provides Earnings Guidance for the Year 2024 The Oncology Institute, Inc. provided earnings guidance for the year 2024. For the year, the company expects revenue to be in the range of $400 million to $415 million. Announcement • Mar 07
The Oncology Institute, Inc. to Report Q4, 2023 Results on Mar 27, 2024 The Oncology Institute, Inc. announced that they will report Q4, 2023 results After-Market on Mar 27, 2024 New Risk • Jan 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$44m net loss in 2 years). Recent Insider Transactions • Dec 19
Key Executive recently bought US$127k worth of stock On the 14th of December, Mihir Shah bought around 100k shares on-market at roughly US$1.27 per share. This transaction increased Mihir's direct individual holding by 7x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Mihir's only on-market trade for the last 12 months. New Risk • Dec 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$95.9m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$44m net loss in 2 years). Market cap is less than US$100m (US$95.9m market cap). Recent Insider Transactions Derivative • Nov 26
Vice Chairman notifies of intention to sell stock Bradford Hively intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of November. If the sale is conducted around the recent share price of US$2.24, it would amount to US$56k. Since March 2023, Bradford has owned 370.85k shares directly. Company insiders have collectively bought US$285k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions Derivative • Nov 17
Vice Chairman notifies of intention to sell stock Bradford Hively intends to sell 47k shares in the next 90 days after lodging an Intent To Sell Form on the 13th of November. If the sale is conducted around the recent share price of US$2.52, it would amount to US$119k. Since December 2022, Bradford has owned 370.85k shares directly. Company insiders have collectively bought US$320k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions Derivative • Nov 16
Vice Chairman notifies of intention to sell stock Bradford Hively intends to sell 47k shares in the next 90 days after lodging an Intent To Sell Form on the 13th of November. If the sale is conducted around the recent share price of US$2.52, it would amount to US$119k. Since December 2022, Bradford has owned 370.85k shares directly. Company insiders have collectively bought US$398k more than they sold, via options and on-market transactions, in the last 12 months. New Risk • Nov 10
New major risk - Revenue and earnings growth Earnings have declined by 61% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 61% per year over the past 5 years. Reported Earnings • Nov 10
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.03 loss in 3Q 2022) Third quarter 2023 results: US$0.24 loss per share (further deteriorated from US$0.03 loss in 3Q 2022). Revenue: US$82.0m (up 26% from 3Q 2022). Net loss: US$17.4m (loss widened US$15.2m from 3Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 6.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 47 percentage points per year, which is a significant difference in performance. Announcement • Oct 19
The Oncology Institute, Inc. to Report Q3, 2023 Results on Nov 08, 2023 The Oncology Institute, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023 Announcement • Oct 14
The Oncology Institute, Inc. Names Jeremy Castle as Chief Operations Officer The Oncology Institute, Inc. announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOIs success as a public company. Mr. Castle joins TOI with over 15 years of oncology industry experience, and has a track record of driving growth and profitability for multi-state physician groups. He has had other senior leadership positions, including Mr. Castle having previously served as the Chief Operating Officer for United Urology Group and Executive Director for The US Oncology Network. New Risk • Sep 22
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$64m). Currently unprofitable and not forecast to become profitable next year (US$65m net loss next year). Market cap is less than US$100m (US$99.2m market cap). Announcement • Sep 19
The Oncology Institute Regains Compliance with Nasdaq Listing Requirements The Oncology Institute, Inc. (the “Company”) announced that it received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) on September 15, 2023, informing the Company that it has regained compliance with the minimum bid price requirement set under Nasdaq Listing Rule 550(a)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market. This follows second quarter 2023 results demonstrating continued strong year over year revenue growth, and announcements on recent technology partnerships with Ambience Healthcare and Massive Bio to drive continued efficiencies and expansion of the business. To regain compliance with the Rule, the Company’s common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. This requirement was met on September 14, 2023. Announcement • Sep 09
The Oncology Institute, Inc. Appoints Jeremy N. Castle as Chief Operations Officer On September 5, 2023, The Oncology Institute, Inc. appointed Jeremy N. Castle to replace Matthew Miller, MD as the Company’s Chief Operations Officer. Dr. Miller’s separation from the Company was effective June 16, 2023, as previously disclosed in that certain Current Report on Form 8-K filed with the Securities and Exchange Commission on May 22, 2023. Jeremy N. Castle, age 40, has worked in the healthcare industry for over 15 years in operations, business development, sales, and executive leadership, primarily in the Phoenix, Arizona region. Prior to joining the Company, he served as Vice President of Operations of OneOncology, headquartered in Nashville, Tennessee, from January 2022 until August 2023. From March 2020 to December 2021, he served as Chief Operating Officer of Arizona Urology Specialists, United Urology Group. Prior to that, he was Executive Director of The US Oncology Network, a position he held from January 2019 to March 2020. He served as Regional Director of Operations of Panoramic Health from June 2018 to December 2019 and as Director of Operations of Ironwood Physicians, PC from October 2014 to June 2018. He also held various leadership roles with California Cancer Associates and Global Nephrology Solutions. His areas of expertise include leading development and integration of long-term growth initiatives, engaging critical stakeholders, forging strategic partnerships, recruiting and retention, risk management, facility accreditation and regulatory compliance, new process implementation, change management, contract negotiations, and human resources management. He holds a Bachelor of Science Degree in Business Administration – Business Management/Finance from the University of Arizona and a Master of Business Administration – Finance from the University of Arizona, Eller College of Management. 
